Media coverage about Tenax Therapeutics (NASDAQ:TENX) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tenax Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 42.1146055652415 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Tenax Therapeutics (NASDAQ:TENX) traded down $0.01 during trading on Thursday, reaching $0.32. The company’s stock had a trading volume of 343,070 shares, compared to its average volume of 409,640. The company has a market capitalization of $9.04, a P/E ratio of -0.21 and a beta of 1.86. Tenax Therapeutics has a 1 year low of $0.30 and a 1 year high of $0.94.
TRADEMARK VIOLATION NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/01/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-tenax-therapeutics-tenx-stock-price.html.
About Tenax Therapeutics
Tenax Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure.
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.